Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $21 price target on Array BioPharma after the company reported an "impressive" one-year overall survival rate of 62% from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer. In a research note to investors, Tenthoff also said he is confident in the approval of Braftovi + Mektovi in BRAF-mutant melanoma by the June 30 PDUFA date.